Business Standard
Saturday, Feb 18, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
  Home  ||||||||| 
 BS Headlines | News Now | BS Weekend | The strategist | smartinvestor.in | E-Paper | SME | Run-up to Budget | Energy | Have Your Say | Cloud Computing | Nasscom
Home > Live Markets | Commodities
 

Ranbaxy gains WHO pre-qualification for Indinavir - 400mg ARV capsules
Announcement / Corporate Nov 12, 2009, 20:05 IST

Ranbaxy Laboratories Limited (Ranbaxy) announced today that the World Health Organisation, Geneva (WHO), has included the Company’s Indinavir (as sulfate) - 400mg Anti Retroviral (ARV) Capsule, in its pre-qualification list.

With this new addition, Ranbaxy now has a total of 19 ARVs on the WHO pre-qualification list.

Commenting on the WHO listing, Ranbaxy's CEO &MD, Mr. Atul Sobti said, "Ranbaxy remains committed to provide high quality affordable generic ARV medicines and will continue to dedicate itself in fighting the worldwide struggle against HIV/AIDS."

Ranbaxy's ARVs, including the recently approved WHO pre-qualified products, are manufactured at the Company's state-of-the-art manufacturing facilities.

Since 2001, Ranbaxy has been providing high quality ARV medicines, at affordable prices , in over 70 markets worldwide, thereby facilitating access to patients afflicted by HIV/AIDS who might not otherwise have been able to gain access to this therapy. The Company's ARVs have been used as mainstays in various large treatment programs, both National and NGO/Institutional with good results. ARV medicine produced by Ranbaxy are used by over 400000 patients worldwide , in various developing and underdeveloped countries.

Ranbaxy is committed to supporting the global fight against HIV/AIDS through high quality, affordable medicines.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 10 countries.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Weekly: Indices surge 3% led by rate sensitives
- 'Cong will meet same fate in Goa polls as in BMC'
- More trouble for Maya's elephants in UP
- FM holds pre-Budget talks with regulators
- Polls show Mumbai can't be separated from M'rashtra: Thackeray
  Read Business news in 
Sorry, comments to this story are closed
Latest Messages
SmartInvestor+ E-zine
  Pay Rs.747/- for 3 years and
  get a branded watch FREE

  Subscribe Now
Most Popular
Read
E-Mailed
Commented
   
- T N Ninan: Saving Mumbai
- Aditi Phadnis: The battle lines for Behenji
- Nissan mulls to launch its top-selling electric car in India
- Kingfisher suspends Kolkata flights
- Deepak Lal: Rights, stakes and Newspeak
 
 More  
BUSINESS STANDARD INDIA 2012
  Now available at Special price
  Rs.395/- Only
  Buy Now
  Now available on the Kindle Store...
  BS Specials  
    Full coverage of elections in Uttar Pradesh, Punjab, Uttarakhand, Manipur and Goa
  Hot Searches  
 
IRFC bond |  Antrix-Devas |  Rafale fighter |  Junglee |  IPL 5 |  Dhanlaxmi Bank |  Thomas Cook |  TCS |  Sarfaesi Act |  Vodafone |  Aakash tablet |  Sodexo |  Rupee |  Samsung Galaxy Note |  Kingfisher Airlines |  Silver |  Provident Fund |  income tax refund |  Anna Hazare |  iPhone |  Reliance Industries |  SEBI |  BSNL |  BSE |  NSE |  Mukesh Ambani |  Anil Ambani |  Infosys |  Pranab Mukherjee |  Sonia Gandhi |  Rahul Gandhi |  New Pension Scheme |  Reliance |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  B-School |  Sensex |  Tax calculator |  Home Loan |  Personal Finance |  inflation |  oil prices |  Barack Obama |   
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us